Versant Venture Management, LLC Long-Term Concentrated

Location: San Francisco, CA

CIK: 0001560009 · Show all filings

Period: Q3 2019 (← Previous) (Next →)

Filing Date: Oct 8, 2019

Total Value: $258.5B (100.0% shares, 0.0% debt)

Holdings (8)

CRSP CRISPR Therapeutics AG 67.1%

Value $173.5B Shares 4,233,870 Est. Cost $40.26 Unrealized +18.7%

VCYT Veracyte, Inc. 11.2%

Value $28.93B Shares 1,205,407 Est. Cost $11.03 Unrealized +141.2%

— Gritstone Oncology, Inc. 10.4%

Value $26.79B Shares 3,102,929 Est. Cost $11140.00 Unrealized —

— Audentes Therapeutics, Inc. 6.0%

Value $15.56B Shares 553,916 Est. Cost $17810.00 Unrealized —

OCUL Ocular Therapeutix, Inc. 2.6%

Value $6.735B Shares 2,215,384 Est. Cost $20.09 Unrealized -77.8%

— Second Sight Medical Products, Inc. 1.4%

Value $3.706B Shares 4,492,975 Est. Cost $1210.00 Unrealized —

— CymaBay Therapeutics, Inc. 1.1%

Value $2.784B Shares 543,753 Est. Cost $9871.60 Unrealized —

— Clovis Oncology, Inc. 0.2%

Value $400M Shares 101,855 Est. Cost $56000.00 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
CRSP	CRISPR Therapeutics AG	4,233,870	$173.5B	67.1%	$40.26	+18.7%	Common Stock	H17182108
VCYT	Veracyte, Inc.	1,205,407	$28.93B	11.2%	$11.03	+141.2%	Common Stock	92337F107
—	Gritstone Oncology, Inc.	3,102,929	$26.79B	10.4%	$11140.00	—	Common Stock	39868T105
—	Audentes Therapeutics, Inc.	553,916	$15.56B	6.0%	$17810.00	—	Common Stock	05070R104
OCUL	Ocular Therapeutix, Inc.	2,215,384	$6.735B	2.6%	$20.09	-77.8%	Common Stock	67576A100
—	Second Sight Medical Products, Inc.	4,492,975	$3.706B	1.4%	$1210.00	—	Common Stock	81362J100
—	CymaBay Therapeutics, Inc.	543,753	$2.784B	1.1%	$9871.60	—	Common Stock	23257D103
—	Clovis Oncology, Inc.	101,855	$400M	0.2%	$56000.00	—	Common Stock	189464100